Article

Hypertonic saline is a promising alternative for LASEK flap creation

Rishon Le-Zion, Israel-LASEK performed by using hypertonic saline (5% NaCl) to lift the flap may be a better alternative to alcohol-assisted LASEK, according to a recent randomized prospective study. Israeli researchers presented clinical trial results of the new method.

Rishon Le-Zion, Israel-LASEK performed by using hypertonic saline (5% NaCl) to lift the flap may be a better alternative to alcohol-assisted LASEK, according to a recent randomized prospective study. Israeli researchers presented clinical trial results of the new method.

"LASEK may hold a solution for avoiding some of the complications associated with LASIK. Substituting hypertonic saline for ethanol may increase epithelial cell viability and seems to allow for quicker recovery and better visual outcomes during the first 2 weeks postoperatively-the period that can be most problematic for patients," said Dr. Hazarbassanov. "However, the new approach is not a panacea; among its limitations is concern about alcohol-induced epithelial toxicity."

"In five eyes (16.6%) in the alcohol group, the alcohol treatment had to be repeated for 10 to 15 additional seconds because theepithelial flap could not be easily peeled. No such events were observed using hypertonic saline," Dr. Hazarbassanov noted.

All ablations were performed with excimer laser (Allegretto scanning-spot laser; WaveLight Laser Technologie AG, Erlangen, Germany). After the ablation, the cornea was flooded with BSS and the flap was repositioned with a blunt-tipped spatula. Patients wore a soft contact lens for 5 to 7 days until re-epithelialization was achieved.

Faster healing seen Although the saline-assisted group had a significantly larger area of corneal erosion on day 1 compared with the alcohol-assisted group, early follow-up showed that the epithelial defect healed at 4.5 days in the saline-assisted eyes versus at 5.8 days in the alcohol- assisted eyes.

Newsletter

Don’t miss out—get Ophthalmology Times updates on the latest clinical advancements and expert interviews, straight to your inbox.

Related Videos
Lisa Nijm, MD, says preoperative osmolarity testing can manage patient expectations and improve surgical results at the 2025 ASCRS annual meeting
At the 2025 ASCRS Annual Meeting, Weijie Violet Lin, MD, ABO, shares highlights from a 5-year review of cross-linking complications
Maanasa Indaram, MD, is the medical director of the pediatric ophthalmology and adult strabismus division at University of California San Francisco, and spoke about corneal crosslinking (CXL) at the 2025 ASCRS annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Taylor Strange, DO, assesses early visual outcomes with femto-created arcuate incisions in premium IOL cases
(Image credit: Ophthalmology Times) ASCRS 2025: Neda Shamie, MD, shares her early clinical experience with the Unity VCS system
Patricia Buehler, MD, MPH, founder and CEO of Osheru, talks about the Ziplyft device for noninvasive blepharoplasty at the 2025 American Society of Cataract and Refractive Surgeons (ASCRS) annual meeting
(Image credit: Ophthalmology Times) ASCRS 2025: Bonnie An Henderson, MD, on leveraging artificial intelligence in cataract refractive surgery
(Image credit: Ophthalmology Times) ASCRS 2025: Gregory Moloney, FRANZO, FRCSC, on rotational stability
Sheng Lim, MD, FRCOphth, discusses the CONCEPT study, which compared standalone cataract surgery to cataract surgery with ECP, at the 2025 ASCRS Annual Meeting.
(Image credit: Ophthalmology Times) ASCRS 2025: Steven J. Dell, MD, reports 24-month outcomes for shape-changing IOL
© 2025 MJH Life Sciences

All rights reserved.